TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02799030
Drug: BF-200 ALA 10%
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical treatment for photodynamic therapy combining drug application and after 3 h of drug incubation subsequent illumination with a broad spectrum light source .
Study: NCT02926430
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo as formulation buffer.
Study: NCT00044668
Drug: AC2993
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive 5 μg AC2993, subcutaneously injected twice daily, for 4 weeks followed by 10 μg AC2993, subcutaneously injected twice daily, during a maintenance period that is expected to continue for at least 11 months.
Study: NCT00349726
Drug: Inositol lower volume
Normalized name: Inositol
DrugBank: Inositol (DB13178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60 mg/kg (1.2ml/kg) of myo-inositol 5% given intravenously over 20 minutes.
Study: NCT00349726
Drug: Inositol higher volume
Normalized name: Inositol
DrugBank: Inositol (DB13178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 120 mg/kg (2.4ml/kg) of myo-inositol 5% given intravenously over 20 minutes.
Study: NCT04273581
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100mg/d，qn，for 14 days.
Study: NCT03053219
Drug: AC0010
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dose of 300mg bid,the two doses are advised to be administered at an interval of 12 hours
Study: NCT01593033
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g sugar in granule form to be given daily for 6 months 0.9 mL palm oil to be given daily for 6 months
Study: NCT01574326
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for 0.8 g sachets of powder for oral suspension or 800 mg tablets
Study: NCT02379806
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01128257
Drug: ibandronate [Bonviva/Boniva]
Approvals — FDA: no, EMA: no, PMDA: no
Description: As prescribed by physician
Study: NCT04447261
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02238626
Drug: Placebo (for MN-166)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02238626
Drug: MN-166
Normalized name: Mn 2+
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04613674
Drug: placebo+chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo+chemotherapy
Study: NCT02939898
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant therapy to recFSH during ovarian stimulation
Study: NCT03001219
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will continue their pre-trial methotrexate therapy at a stable dose.
Study: NCT03001219
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive intravenous infusion of placebo.
Study: NCT03001219
Drug: RO7123520
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive intravenous infusion of RO7123520.
Study: NCT01403064
Drug: 0.9% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV Infusion
Study: NCT02528123
Drug: Proxymetacaine 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proxymetacaine 0.5% eye drops will be used as an anaesthetic during the procedure
Study: NCT02528123
Drug: Oxybuprocaine 0.4%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxybuprocaine 0.4% eye drops will be used as an anaesthetic during the procedure
Study: NCT01195103
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: All patients will receive a single dose of IV fentanyl (approximately 1 μg/kg not to exceed: 50 μg for patients \<60 kg; 75 μg for patients ≥90 kg) five minutes prior to the initial dose of sedative.
Study: NCT00862745
Drug: Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be instructed to take one tablet of blinded study medication once a day, orally, for 12 weeks. They will start with a 4 mg dose of study medication and will have the option of doubling that dose after 2 or 4 weeks if they wish. At the end of the 12 week blinded trial, participants will be offered open-label fesoterodine (Toviaz™), for 9 months beginning at 4 mg with participant directed dose adjustment.
Study: NCT00548925
Drug: ABT-894
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg BID tablets, 8 weeks of treatment
Study: NCT00548925
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: BID tablets, 8 weeks of treatment
Study: NCT01939496
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One matching placebo capsule orally in addition to the patient's anti-hyperglycemic agents (AHA) regimen used in accordance with local prescribing information.
Study: NCT03178526
Drug: Lovastatin gel
Normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lovastatin gel1.2% topical gel was put into teh periodontal pocket using an insulin syringe
Study: NCT03178526
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo gel
Study: NCT04250948
Drug: JS001
Normalized name: Janus Kinase Inhibitor JS001
Approvals — FDA: no, EMA: no, PMDA: no
Description: JS001, recombinant humanized anti-PD-1 monoclonal antibody for injection; 240mg ivdrip, d1, q3w.
Study: NCT04250948
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine: 1000mg/m2 Bid，d1-14, q3w
Study: NCT03052322
Drug: MSB11022
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received MSB11022 (modified buffer and stabilizer) subcutaneously at dose of 40 milligram (mg) every other week from Day 1 up to Week 48.
Study: NCT03052322
Drug: EU-Humira
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received EU-Humira subcutaneously at dose of 40 mg every other week from Day 1 up to Week 48.
Study: NCT02398357
Drug: Nadroparin Calcium and Warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will take warfarin started at a dose of 2.5mg/d and with titration of dose to maintain a target INR of 2-3,alone with Nadroparin Calcium 4100IU／d，subcutaneous, when taking endoscopy therapy .
Study: NCT00345735
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04326348
Drug: TQ05105
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQ05105 is a JAK2 inhibitor.
Study: NCT00589563
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 60mg/kg on days -5 and -4 from stem cell transplant
Study: NCT00589563
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: For high risk HLA-mismatch transplant only: 5 mg/m2 on days +1, +3 and +6 from stem cell transplant
Study: NCT03000218
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day 1 to 56: Placebo bid
Study: NCT01610544
Drug: 3'-deoxy-3'-18F fluorothymidine (FLT)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00003093
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003093
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00469157
Drug: Optive
Normalized name: optive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optive 30ml- (in the eye) Instill one in each eye twice daily starting one week after surgery
Study: NCT00774696
Drug: clarithromycin 500mg tablets
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00874003
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablet, 1 daily
Study: NCT01988506
Drug: Interleukin 2
Normalized name: Recombinant interleukin 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction period: repeated administration of low-dose IL-2 (1MUI/day, sc) during 5 consecutive days.Maintenance period: treatment with IL-2, 1MUI once every 15 days (except systemic lupus erythematosus's patients every 7 days) for 6 months
Study: NCT04642937
Drug: Treatment with hP1A8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with hP1A8
Study: NCT02717858
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injected s.c./subcutaneously (under the skin) once daily.
Study: NCT00563251
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00563251
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00732615
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for subcutaneous injection
Study: NCT00732615
Drug: NPSP558
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parathyroid hormone 50, 75, or 100 mcg injectable subcutaneously daily
Study: NCT00204607
Drug: GM-CSF s.c.
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00413686
Drug: AZD7762
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous infusion
Study: NCT00063635
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily
Study: NCT02059018
Drug: COX-inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of 1 drop voltaren 45 minutes before recordings of diameter changes of retinal vessels are initiated
Study: NCT03577704
Drug: HLX07+mFOLFOX6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant anti-EGFR humanized monoclonal antibody in combination with Oxaliplatin, Calcium Folinate and 5-FU.~HLX07, IV, weekly.
Study: NCT01103622
Drug: AZD1656
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet bd, step-wise increased dosage
Study: NCT01103622
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet bd, step-wise increased dosage
Study: NCT02758522
Drug: Once-daily Insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive NPH insulin in a once-daily regimen. The starting dose is calculate according to body mass index (BMI): 0.3 U/kg for BMI \< 18 kg/m2, 0.4 U/kg for BMI 18-24.9 kg/m2, 0.5 U/kg for BMI 25-29.9 kg/m2 and 0.6 U/kg for BMI ≥ 30 kg/m2. The resulting dose will be fractioned to be given 60% as basal insulin (NPH) and 40% as prandial insulin (Regular). NPH insulin in the once-daily regimen will be administered subcutaneously before breakfast. Regular insulin subcutaneously wil be given in three equally divided doses before each meal.
Study: NCT02758522
Drug: Twice-daily Insulin
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients receive NPH insulin in twice-daily regimen. The starting dose is calculated according to body mass index (BMI): 0.3 U/kg for BMI \< 18 kg/m2, 0.4 U/kg for BMI 18-24.9 kg/m2, 0.5 U/kg for BMI 25-29.9 kg/m2 and 0.6 U/kg for BMI ≥ 30 kg/m2. The resulting dose will de fractioned to be given 60% as basal insulin (NPH) and 40% as prandial insulin (Regular). NPH insulin in the twice-daily regimen will be administered subcutaneously before breakfast and before dinner. Regular insulin will be given in three equally divided doses before each meal.
Study: NCT02758522
Drug: Triple-daily Insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receive NPH insulin in a triple-daily regimen. The starting dose was calculated according to body mass index (BMI): 0.3 U/kg for BMI \< 18 kg/m2, 0.4 U/kg for BMI 18-24.9 kg/m2, 0.5 U/kg for BMI 25-29.9 kg/m2 and 0.6 U/kg for BMI ≥ 30 kg/m2. The resulting dose will be fractioned to be given 60% as basal insulin (NPH) and 40% as prandial insulin (Regular). NPH insulin in the triple daily regimen will be administered subcutaneously before each meal. Regular insulin will be given in three equally divided doses before each meal.
Study: NCT00306150
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is used according to the description of Arm 1
Study: NCT00988065
Drug: Placebo run-in dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-blind placebo intravenous bolus injection on Day 1 of the study, 7 days prior to randomization
Study: NCT00988065
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo intravenous bolus injection on Day 8, Day 36, and Day 78 of the study
Study: NCT03979820
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Film-coated tablet
Study: NCT00706381
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV and/or oral placebo
Study: NCT01555008
Drug: LX4211
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive LX4211 once daily for 7 days
Study: NCT01555008
Drug: LX4211 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive LX4211 placebo once daily for 7 days
Study: NCT01483469
Drug: RO4917523
Approvals — FDA: no, EMA: no, PMDA: no
Description: orally daily, 14 days
Study: NCT01483469
Drug: RO5011232
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[11C\]-RO5011232 intravenously
Study: NCT04262661
Drug: NNC0472-0147
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part 1: A single dose of NNC0472-0147, dose increased in each cohort. Part 2: Daily doses of NNC0472-0147, dose increased in each cohort.
Study: NCT04262661
Drug: Placebo (NNC0472-0147)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part 1: A single dose of placebo, dose increased in each cohort.
Study: NCT00453817
Drug: ferucarbotran (iron-based MRI contrast agent)
Approvals — FDA: no, EMA: no, PMDA: no
Description: islets will be incubated with ferucarbotran prior to transplantation, for imaging after transplantation
Study: NCT02487381
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04435106
Drug: Standard of Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study participants received Standard of Care
Study: NCT00110162
Drug: antiandrogen therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02547402
Drug: pravastatin
Normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: It is statin medicine used to lower cholesterol and triglycerides in the blood.
Study: NCT02547402
Drug: Vytorin® (combination of simvastatin and ezetimibe)
Approvals — FDA: no, EMA: no, PMDA: no
Description: It lowers bad cholesterol in the blood, and raises good cholesterol
Study: NCT00513682
Drug: Ultrase® MT20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrase® MT20 capsules will be administered orally with each meal during Day 1 to 15 in screening phase at a dose based on investigator's discretion. During Day 12 to 15, participants will receive high-fat diet and Ultrase® MT20 dose will be adjusted depending on symptoms of steatorrhea. This will be followed by a washout phase of 6 to 7 days, in which participants will receive only high-fat diet; then stabilized dose of Ultrase® MT20 capsule (as identified during screening phase) will be administered orally for 7 to 11 days during treatment phase. The stabilized dose should not to exceed 2500 lipase units per kilogram body weight per meal (lipase units/kg/meal).
Study: NCT02317549
Drug: LB1148
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02317549
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02539277
Drug: Jinyebaidu granule
Approvals — FDA: no, EMA: no, PMDA: no
Description: It is a chinese patent medicine extracted from four herbs: honeysuckle, isatis leaf, dandelion, and houttuynia cordata thunb.
Study: NCT02539277
Drug: Fufangshuanghua granule
Approvals — FDA: no, EMA: no, PMDA: no
Description: It is a Chinese patent medicne extracted from four herbs: honeysuckle, forsythia, radix Isatidis, andrographis paniculata.
Study: NCT02539277
Drug: Jinyebaidu granule placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: It is Jinyebaidu granule placebo.
Study: NCT02539277
Drug: Fufangshuanghua granule placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: It is Fufangshuanghua granule placebo.
Study: NCT00293644
Drug: Diclectin®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will begin with an initial dose of 20mg (2 tablets), taken at bedtime. The dose of Diclectin® will be adjusted to match symptoms.
Study: NCT01598012
Drug: Ayurved Siriraj Prasaplai with or without mefenamic acid
Normalized name: E-Z Scrub with Ultradex Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasaplai in capsule, 2 cap three times a day for 3 days. Mefenamic acid 500 mg prn for severe pain (as rescue medication)
Study: NCT01598012
Drug: Placebo with or without mefenamic acid
Normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in capsule (physically identical appearance as Prasaplai) 2 cap three times a day for 3 days. Mefenamic acid 500 mg prn for severe pain, every 6 hours (rescue medication)
Study: NCT00722033
Drug: 3 protocols of Indomethacin administration
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indomethacin will consecutive be infused in 30, 60 and 120 minutes in each patient who requires it.
Study: NCT00530764
Drug: Sativex Medium Dose
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Range of 6 to 10 sprays per day. Each actuation of oromucosal spray delivers 2.7mg delta-9-tetrahydrocannabinol (THC) and 2.5mg cannabidiol (CBD). Thus maximum daily dose is 27mg THC and 25mg CBD.
Study: NCT00712205
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily 1mcg Placebo for 28days followed by crossover treatment
Study: NCT04495283
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen is a non-salicylate antipyretic and non-opioid analgesic agent.
Study: NCT01301586
Drug: Doxycycline and S-equol
Normalized name: S-equol
DrugBank: Equol (DB11674)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral doxycycline and s-equol twice a day
Study: NCT01301586
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ORAL DOXYCYCLINE TWICE A DAY
Study: NCT00796263
Drug: HAART
Normalized name: porcine heart preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 nuceloside/nucleotide analog reverse-transcriptase inhibitor (NRTI) class medications or Kivexa (ABC300/3TC300) orally once daily~Dolutegravir(DTG) 50 mg orally once daily
Study: NCT01428050
Drug: 3% NaCl Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1cc/kg/hr of 3%NaCl + 9cc/kg/hr of lactated ringers solution
Study: NCT02470390
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lazanda (nasal spray), Subsys (sub-lingual) and intravenous fentanyl
Study: NCT00721552
Drug: Prednisolone 30 mg
Normalized name: prednisolone 30 MG
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 14 days administration of 30 mg daily
Study: NCT00721552
Drug: Prednisolone-placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14 days administration once daily
Study: NCT00759811
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients receiving conventional treatment to heart failure who will receive methotrexate 7.5mg oral plus folic acid 5mg oral once a week for 12 weeks.~All patients will have evaluated at the baseline and after 12 weeks: physical capacity by the 6-minutes walk test, quality of life by the Brazilian edition SF-36 and inflammatory marker by C-reactive protein. They also will be tested for ALT, AST, blood cell count, creatinine, and prothrombin time at baseline, after 6 weeks and after 12 weeks.
Study: NCT00759811
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receiving conventional treatment to heart failure who will receive placebo oral plus folic acid 5mg oral once a week for 12 weeks.~All patients will have evaluated at the baseline and after 12 weeks: physical capacity by the 6-minutes walk test, quality of life by the Brazilian edition SF-36 and inflammatory marker by C-reactive protein. They also will be tested for ALT, AST, blood cell count, creatinine, and prothrombin time at baseline, after 6 weeks and after 12 weeks.
Study: NCT04132583
Drug: Deflox®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received a single oral dose of 50 mg Deflox® tablet in either treatment period 1 or 2 under fasting conditions.
Study: NCT04132583
Drug: Cataflam DD®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received a single oral dose of 50 mg Cataflam DD® tablet in either treatment period 1 or 2 under fasting conditions.
Study: NCT03858166
Drug: PEG-rhG-CSF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6mg PEG-rhG-CSF was administrated subcutaneously at different time after chemotherapy.
Study: NCT00345059
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00220402
Drug: SPM 907
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01310673
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet QD for 10 days, followed by delayed allopurinol 300mg po QD days 11-30.~Indomethacin 50mg TID for 10 days. Colchicine 0.6mg po Bid or QD, as tolerated for 90 days.
Study: NCT03219931
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is the placebo product containing a similar product without bifidobacterium inside.
Study: NCT03242460
Drug: Cyclophosphamide 400mg
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide 400mg Days 1, 8, 15
Study: NCT00085774
Drug: placebo aerosol by HFA
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo HFA
Study: NCT03680573
Drug: Control: Lacated Ringers
Approvals — FDA: no, EMA: no, PMDA: no
Description: This site will serve as the control site
Study: NCT03728634
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo comparator calculated volume to match ION-682884 administered SC
Study: NCT03680573
Drug: NG Nitro L Arginine Methyl Ester
Normalized name: methyl L-arginine
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-Name is a NOS inhibitor that is administered to each site to allow for the quantification of NO contribution to vasodilation. The infusion rate will be 2 µl/min
Study: NCT03680573
Drug: Acetyl-ß-methylcholine chloride
Normalized name: Acetyl-beta-methylcholine
DrugBank: Methacholine (DB06709)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mch is an acetylcholine analog that causes endothelial dependent vasodilation primarily through stimulation of NO production.
Study: NCT04941339
Drug: MRG002
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administrated intravenously
Study: NCT01776463
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no